RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension

Hypertension, Renal Clinical Trial

Official title:

A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01756300
• Other study ID #: RENABLATE
• Status: Completed
• Phase: Phase 1
• First received: December 20, 2012
• Last updated: October 15, 2015
• Start date: December 2012
• Est. completion date: April 2015

Study information

• Verified date: October 2015
• Source: Biosense Webster, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Czech Republic: State Institute for Drug ControlBelgium: Federal Agency for Medicines and Health Products, FAMHPDenmark: Danish Health and Medicines AuthorityGermany: Federal Institute for Drugs and Medical DevicesItaly: The Italian Medicines AgencyAustralia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

The RENABLATE feasibility study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of the investigational multi-electrode ablation catheter and integrated ablation system to treat resistant hypertension.

Description:

The RENABLATE feasibility study CS156 (EC12-02) is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of renal artery sympathetic denervation using the investigational Celsius® ThermoCool® Renal Denervation (RD) Multi-electrode Ablation Catheter and integrated ablation system to treat resistant hypertension.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: April 2015
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 84 Years

Eligibility

Inclusion Criteria:

1. Subject is > 18 and < 85 years old.

2. Individual has a systolic blood pressure = 160 mmHg (= 150 mmHg for type 2 diabetics) based on an average of 3 office blood pressure readings.

3. Individual is adhering to a stable drug regimen of at least 3 different classes of anti-hypertensive medications, including a diuretic (with no changes for a minimum of 2 weeks prior to enrollment) at optimal dose and is expected to be maintained for at least 6 months.

4. Individual agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this study.

Exclusion Criteria:

1. Subjects with known/diagnosed secondary hypertension.

2. Subject has 'White Coat' hypertension defined as 24 hour daytime systolic blood pressure <135 mm Hg as evaluated at Baseline visit.

3. Subject has aorto-ilio-femoral artery anatomy not suitable for treatment with the investigational Celsius® ThermoCool® RD Multi-electrode Ablation Catheter.

4. Subject has main renal arteries that are < 20 mm in length or < 4 mm in diameter.

5. Subject has multiple main renal arteries in either kidney.

6. Subject has a history of prior renal artery intervention including balloon angioplasty, stenting or surgery.

7. Subject had a previous kidney transplant or is a planned recipient of a transplant kidney or is on dialysis.

8. Subject has a past history of unilateral kidney removal or has a solitary functional kidney for any other reason.

9. Subject has an estimated glomerular filtration rate (eGFR) of < 45mL/min/1.73m2, using the MDRD formula.

10. Subject has type 1 diabetes mellitus.

11. Subject has history of Myocardial Infarction, unstable angina pectoris, or a cerebrovascular accident in the 6 months period prior to enrolment, or documented widespread atherosclerosis, intravascular thrombosis or unstable plaques.

12. Subject had a significant surgery or cardiovascular intervention in the 6 months period preceding enrollment or is planned to have such a surgery or cardiac intervention in the 6 months period post enrollment.

13. Subject has hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous.

14. Subject is taking systemic steroids or chronic daily NSAIDs.

15. Subject has a known allergy to Aspirin and/or other procedural drugs or contrast agents which in the investigator's opinion excludes him/her from the study.

16. Subject has a serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study (e.g., subjects with active systemic infection, subjects with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, or significant anemia).

17. Women of childbearing potential with a positive pregnancy test during screening OR women who do not agree to remain on birth control until follow-up at 6 months OR lactating women.

18. Subject has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.

19. Subject is currently enrolled in another investigational drug or device trial.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Renal

Intervention

Device:
• Celsius® ThermoCool® RD
The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.

Locations

Country	Name	City	State
Australia	Peninsula Heart Centre	Frankston	Victoria
Belgium	Onze-Lieve-Vrouwziekenhuis Aalst	Aalst
Belgium	Ziekenhuis Oost-Limburg	Genk
Czech Republic	Charles University Hospital	Prague
Czech Republic	Na Homolce Hospital	Prague
Denmark	Aarhus University Hospital, Skejby Sygehus	Aarhus
Italy	Ospedale Generale Regionale	Bari

Sponsors (1)

Lead Sponsor	Collaborator
Biosense Webster, Inc.

Countries where clinical trial is conducted

Australia,  Belgium,  Czech Republic,  Denmark,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Incidence of Major Cardiovascular and/or Renal Adverse Events Related to the Renal Denervation Procedure That Occurred Within 30 Days Post-procedure.	The major adverse events include Acute myocardial infarction, Death from progressive heart failure, death from aortic or peripheral artery disease, from renal failure and sudden cardiac death, New-onset heart failure, Stroke, Aortic or lower limb, revascularization procedure, Lower limb amputation, Beginning dialysis, Hospital admission for hypertensive emergency unrelated to non-adherence or non-persistence with drugs at each follow up visit, Hospitalization for atrial fibrillation.	30 days post-procedure	Yes
Secondary	Subjects Experienced Any Adverse Cardiovascular and Renal Events Through 12 Months Post-procedure	These adverse events include renal artery stenosis (=60% diameter reduction confirmed by MRI or renal angiography); periprocedural renal artery dissection or perforation requiring intervention, serious arterial access site related complications requiring intervention or prolonging hospitalization; =25% reduction between baseline and 12 months in renal function measured by the estimated Glomerular Filtration Rate (eGFR), as well as composite of major adverse cardiovascular and/or renal events.	12 months post-procedure	Yes
Secondary	Actual and Change in Office Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to 1 ,3, 6 and 12 Months Post Procedure	This secondary effectiveness endpoint is defined as actual and change in office systolic blood pressure and diastolic blood pressure from baseline to 1 ,3, 6 and 12 months post procedure. Negative values represent reduction from baseline.	From baseline to 1 ,3, 6 and 12 months post procedure	No
Secondary	Actual and Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure and Diastolic Blood Pressure From Baseline to 3, 6 and 12 Months Post Procedure	This secondary effectiveness endpoint is defined as change in 24-hour ABPM systolic blood pressure and diastolic blood pressure from baseline to 3, 6 and 12 months post procedure. The blood pressures were measured using the 24-hour Ambulatory Blood Pressure Monitoring system. Reported values are the arithmetic mean of collected blood pressure values over 24 hours. Negative values represent reduction from baseline.	From baseline to 3, 6 and 12 months post procedure	No
Secondary	Incidence of Subjects Achieving Target Systolic Blood Pressure at 1, 3, 6, and 12 Month Post-procedure	This endpoint is defined as incidence of subjects achieving target systolic blood pressure at 1, 3, 6, and 12 month post-procedure. Target systolic blood pressure is defined as less than 140 mmHg (and less than 130 mmHg for Type II Diabetics).	At 1, 3, 6, and 12 month post-procedure	No
Secondary	Incidence of Subjects Achieving at Least 10 mmHg Systolic Blood Pressure Reduction From Baseline at 1, 3, 6, and 12 Month Post-procedure	This endpoint is defined as Incidence of subjects achieving at least 10 mmHg systolic blood pressure reduction from Baseline at 1, 3, 6, and 12 month post-procedure	At 1, 3, 6, and 12 month post-procedure	No